Skip to main content
SpringerLink
Log in

Exenatide trumps insulin glargine in cost effectiveness

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International Journal of Clinical Pharmacology and Therapeutics 47: 501-515, No. 8, Aug 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Exenatide trumps insulin glargine in cost effectiveness. Pharmacoecon. Outcomes News 586, 1 (2009). https://doi.org/10.2165/00151234-200905860-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905860-00001

Keywords

Search

Navigation